Via Reuters:
" U.S. health regulators are reviewing potential risks of medicines from Roche Holding AG, Novartis AG and other companies.
The Food and Drug Administration said on Wednesday it was probing reports of hearing loss with Novartis cancer drug Gleevec, hypothermia with Roche's flu drug Tamiflu and pericarditis with Biogen Idec and Elan Corp's multiple sclerosis drug Tysabri."
The whole article:
http://www.reuters.com/article/idUSTRE61H0DE20100218
No comments:
Post a Comment